2 research outputs found
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Daratumumab showed promising efficacy alone and with lenalidomide and dexamethasone in a phase 1-2 study involving patients with relapsed or refractory multiple myeloma.info:eu-repo/semantics/publishe
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
The combination melphalan-prednisone-thalidomide (MPT) is considered a standard therapy for patients with myeloma who are ineligible for stem-cell transplantation. However, emerging data on the use of lenalidomide and low-dose dexamethasone warrant a prospective comparison of the two approaches.0info:eu-repo/semantics/publishe